Mereo BioPharma reported a net loss of $19.6 million for the nine months ended September 30, 2026, an improvement from the $34.5 million loss in the prior year period. Cash and cash equivalents decreased to $26.1 million from $41.0 million at the end of 2025, primarily driven by research and development expenses for its rare disease clinical programs.
Mereo BioPharma reported third quarter 2026 financial results and provided updates on its rare disease pipeline, including setrusumab for osteogenesis imperfecta and alvelestat for AATD-LD. The company ended the quarter with $26.1 million in cash, which is expected to fund operations into late-2027, excluding potential milestone payments from partners Ultragenyx and Sentynl Therapeutics.
“During the third quarter, we have made meaningful progress on our two core programs, setrusumab and alvelestat. These developments have the potential to set the stage for a transformational 2027 for Mereo, our shareholders and the patients we aim to serve.”
Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma